
Nivolumab combined with ipilimumab safe as first-line therapy for lung cancer patients
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a…
Combining the PD-1 immune check point inhibitor nivolumab with the monoclonal antibody ipilimumab showed a…